Strengthening the Management Base Through Business Structural Reform
First written in FY2018-Q2. 11 of 20 entries say "Restated". Latest entry: FY2025-H1.
22 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「The Company aims to recover revenue by expanding contract manufacturing of specified cell-processed products and acquiring new CDMO projects, while reducing costs through optimization of its production structure and improving the efficiency of selling expenses.」
As part of its business structural reforms, the Company continues to pursue expanded contract manufacturing, new CDMO projects, production structure optimization, cost reductions and greater efficiency in selling expenses. - FY2024-Q2RestatedAnnual report
「Through the business structural reforms implemented in April 2018, the Company has optimized its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through the consolidation and closure of cell processing facilities, among other measures. - FY2023RestatedAnnual report
「The Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues to optimize its production structure through facility consolidation and closure, among other measures, but the cell processing business segment's loss widened in the current fiscal year. - FY2023-Q3RestatedAnnual report
「However, the Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through the consolidation and closure of cell processing facilities, among other measures. - FY2023-Q1RestatedAnnual report
「However, the Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through the consolidation and closure of cell processing facilities, among other measures. - FY2022-Q3RestatedAnnual report
「The Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through facility consolidation and closure, among other measures. - FY2022-Q2RestatedAnnual report
「The Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through the consolidation and closure of cell processing facilities, among other measures. - FY2022-Q1RestatedAnnual report
「The Company has steadily implemented the business structural reforms launched in April 2018 and, in the cell processing business segment, has optimized its production structure through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures.」
The Company continues the business structural reforms launched in April 2018 and the optimization of its production structure through facility consolidation and closure and the solicitation of voluntary retirements, among other measures. - FY2021-Q3RestatedAnnual report
「Through the steady implementation of its business structural reforms, the Company has been optimizing its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures.」
The Company continues business structural reforms, including facility consolidation and closure and the solicitation of voluntary retirements. - FY2021-Q2RestatedAnnual report
「Through the steady implementation of its business structural reforms, the Company has been optimizing its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures.」
The Company continues business structural reforms, including facility consolidation and closure and the solicitation of voluntary retirements. The cell processing business segment was loss-making during the cumulative second-quarter period, and the Company is working to restore profitability. - FY2021-Q1RestatedAnnual report
「Through the steady implementation of its business structural reforms, the Company has been optimizing its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures.」
The Company continues business structural reforms, including facility consolidation and closure and the solicitation of voluntary retirements. Meanwhile, the cell processing business segment was loss-making in the current first quarter, and the Company is working to restore profitability. - FY2020-Q3AdvancedAnnual report
「By steadily implementing the business structural reforms launched in April 2018, the Company optimized its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures, and achieved segment profitability in the cumulative third-quarter period, continuing from the previous fiscal year.」
The Company continued business structural reforms, including facility consolidation and closure and the solicitation of voluntary retirements, and achieved profitability in the cell processing business segment during the cumulative third-quarter period. - FY2020-Q2AdvancedAnnual report
「By steadily implementing the business structural reforms launched in April 2018, the Company optimized its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures, and achieved segment profitability in the cumulative second-quarter period, continuing from the previous fiscal year.」
The Company continued business structural reforms, including facility consolidation and closure and the solicitation of voluntary retirements, and achieved profitability in the cell processing business segment during the cumulative second-quarter period. - FY2020-Q1AdvancedAnnual report
「In the cell processing business segment, the Company optimized its production structure through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures, and achieved segment profitability in the cumulative first-quarter period, continuing from the previous fiscal year.」
Structural reform measures continued, and the cell processing business segment was confirmed to have returned to profitability in the first quarter. - FY2019AdvancedAnnual report
「By steadily implementing the business structural reforms launched in April 2018, the Company optimized its production structure in the cell processing business segment through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, among other measures, and achieved segment profitability in the current fiscal year.」
Structural reforms, including facility consolidation and closure, voluntary retirements and workforce allocation optimization, progressed, and the cell processing business segment became profitable. - FY2019-Q3AdvancedAnnual report
「The Company has steadily implemented the business structural reforms launched in April of the previous year. In the disclosed cell processing business segment, it is optimizing its production structure through the consolidation and closure of cell processing facilities and the solicitation of voluntary retirements, and is working to bring the segment into the black.」
The Company explained that it was implementing facility consolidation and closure and soliciting voluntary retirements as part of its business structural reforms, while optimizing its production structure and working to make the cell processing business segment profitable. - FY2019-Q2AdvancedAnnual report
「The Shin-Yokohama and Osaka cell culture and processing facilities were consolidated by March 2019 into the Shinagawa Cell Culture and Processing Facility, which has one of the largest manufacturing capacities in Japan. Going forward, by handling everything from cell processing for medical institutions to the manufacture of regenerative medicine products, the company aims to improve the efficiency of its manufacturing structure in the cell processing business and achieve break-even in the cell processing business segment for the fiscal year ending September 2019.」
The Company implemented facility consolidation, a key measure in its business structural reforms, and progressed to the stage of targeting break-even earnings for the cell processing business segment in the fiscal year ending September 2019. - FY2019-Q1AdvancedAnnual report
「In addition, as earnings improved significantly through structural reforms, including the consolidation of cell culture and processing facilities and optimization of staffing, revenue was ¥246 million and the segment loss was ¥9 million.」
Structural reform measures emerged as an improvement in the cell processing business segment's earnings, resulting in a segment loss of ¥9 million. - FY2018-Q3AdvancedAnnual report
「The Company decided to implement business structural reforms and has begun carrying them out.」
Following a Board of Directors resolution dated 27 April 2018, the Company moved structural reforms, including facility consolidation, strengthening of its product development structure, narrowing its R&D themes and soliciting voluntary retirements, into the implementation phase. - FY2018-Q2First statedAnnual report
「To improve this situation, we decided to implement business restructuring and have begun executing it.」
The Company decided to implement business restructuring to improve continuing operating losses and negative operating cash flow and began execution.